Publication | Closed Access

Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein–Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells

Epstein–barr VirusTumor BiologyLymphoid NeoplasiaMedicineLymphoma CellsImmunologyTumor ImmunityPathologyCell DeathImmune SurveillanceCancer BiologyMdm2 AntagonistsCancer ResearchViral OncologyCancer-associated Virus